Enovis Corporation (NYSE:ENOV) is highlighted as one of the best medical device stocks to buy according to analysts. UBS recently lowered the price target on ENOV to $57 from $65, maintaining a Buy rating. The company reported fiscal Q2 2025 earnings, with net sales reaching $565 million, reflecting 7% growth on a reported basis and 5% on an organic basis compared to the previous year. Management attributes the positive results to stable end markets, strong performance in P&R and Recon segments, and momentum in new product introductions. ENOV focuses on developing innovative medical technology solutions to improve patient outcomes.

Read more at Yahoo Finance: UBS Lowers PT on Enovis Corporation (ENOV) to $57 From $65, Keeps a Buy Rating